Skip to main content
letter
. 2017 Dec 20;7(12):659. doi: 10.1038/s41408-017-0023-x

Fig. 1.

Fig. 1

Flow cytometric profiles of blasts from four patients with CD19-negative relapse after blinatumomab treatment and one control patient during treatment. a Patient #1, b Patient #2, c Patient #3, d Patient #4, and e control patient